BioCardia (NASDAQ:BCDA) Upgraded at Wall Street Zen
by Teresa Graham · The Cerbat GemWall Street Zen upgraded shares of BioCardia (NASDAQ:BCDA – Free Report) to a sell rating in a research report report published on Saturday.
Several other research analysts also recently commented on BCDA. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of BioCardia in a research note on Tuesday, June 9th. Zacks Research lowered shares of BioCardia from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of BioCardia in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Reduce” and an average price target of $25.00.
Check Out Our Latest Analysis on BCDA
BioCardia Price Performance
Shares of BCDA stock opened at $0.90 on Friday. BioCardia has a 1 year low of $0.78 and a 1 year high of $2.42. The firm has a fifty day moving average price of $0.97 and a 200-day moving average price of $1.14. The company has a market cap of $10.30 million, a price-to-earnings ratio of -0.99 and a beta of 0.44.
BioCardia (NASDAQ:BCDA – Get Free Report) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.04). Equities research analysts expect that BioCardia will post -0.76 EPS for the current year.
Insider Buying and Selling at BioCardia
In other BioCardia news, Director Simon H. Stertzer bought 70,200 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of $0.92 per share, for a total transaction of $64,584.00. Following the completion of the transaction, the director owned 127,338 shares of the company’s stock, valued at $117,150.96. This trade represents a 122.86% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders bought a total of 145,900 shares of company stock valued at $138,862 over the last three months. Corporate insiders own 17.40% of the company’s stock.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in BCDA. Cetera Investment Advisers purchased a new stake in BioCardia during the 2nd quarter valued at approximately $40,000. DRW Securities LLC purchased a new position in shares of BioCardia in the fourth quarter worth $72,000. Finally, Geode Capital Management LLC lifted its holdings in shares of BioCardia by 70.4% in the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock worth $83,000 after buying an additional 27,263 shares in the last quarter. 20.57% of the stock is currently owned by institutional investors.
BioCardia Company Profile
BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.
The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.